Iterum Therapeutics (NASDAQ:ITRM) versus Ensysce Biosciences (NASDAQ:ENSC) Critical Review

Iterum Therapeutics (NASDAQ:ITRM) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Iterum Therapeutics and Ensysce Biosciences, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1	2	0	0	1.67
Ensysce Biosciences	1	0	2	0	2.33

Ensysce Biosciences has a consensus price target of $2.00, indicating a potential upside of 416.53%. Given Ensysce Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Ensysce Biosciences is more favorable than Iterum Therapeutics.

Valuation & Earnings

This table compares Iterum Therapeutics and Ensysce Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04
Ensysce Biosciences	$5.07 million	1.49	-$10.18 million	($2.76)	-0.14

Ensysce Biosciences has higher revenue and earnings than Iterum Therapeutics. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Iterum Therapeutics has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500. Comparatively, Ensysce Biosciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Profitability

This table compares Iterum Therapeutics and Ensysce Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%

Institutional & Insider Ownership

9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Iterum Therapeutics beats Ensysce Biosciences on 8 of the 14 factors compared between the two stocks.

About Iterum Therapeutics

Iterum Therapeutics plc (NASDAQ:ITRM) is an Ireland-based pharmaceutical company focused on developing and commercializing anti-infective therapies for infections caused by drug-resistant bacteria. The company’s lead product is sulopenem, a penem-class antibiotic designed to provide activity against a broad range of pathogens. In 2024, the U.S. Food and Drug Administration approved Orlynvah, an oral combination of sulopenem etzadroxil and probenecid, for the treatment of uncomplicated urinary tract infections in adult women when alternative oral antibacterial treatments are not suitable.

About Ensysce Biosciences

Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing prescription medicines designed to address opioid abuse, misuse and overdose. The company’s technology is intended to preserve the therapeutic benefits of opioid pain medicines while incorporating mechanisms that may reduce the risks associated with tampering or excessive dosing. Ensysce’s lead product candidate, PF614, is an investigational extended-release oxycodone prodrug designed to be activated in the gastrointestinal tract.